Loading clinical trials...
Loading clinical trials...
Open-Label, Single-Arm, Multicenter Study to Evaluate Long-Term Safety and Tolerability of Brivaracetam Used as Adjunctive Treatment in Pediatric Study Participants With Epilepsy
Conditions
Interventions
Brivaracetam
Locations
36
United States
Ep0156 259
Hawthorne, New York, United States
Ep0156 237
Durham, North Carolina, United States
Ep0156 204
Leuven, Belgium
Ep0156 240
Prague, Czechia
Ep0156 207
Loos, France
Ep0156 209
Freiburg im Breisgau, Germany
Start Date
March 11, 2021
Primary Completion Date
July 8, 2030
Completion Date
July 8, 2030
Last Updated
June 27, 2025
NCT06315322
NCT06700356
NCT02531880
NCT05289934
NCT05871372
NCT07116330
Lead Sponsor
UCB Biopharma SRL
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions